Tag
This paper argues that AI-native biotech companies should use a core computational abstraction called a Company World Model rather than mimicking human department structures. It introduces a dry-lab benchmark comparing architectures and finds that a value-conversion architecture outperforms human-org mimics, but results are objective-sensitive.
CAPABLE is an AI-driven lab that can go from drug design to data in 24 hours, starting with short-sleeper peptides. The project aims to turn AI capabilities into human capabilities for drug development.
Anthropic announced Claude Science, an AI workbench for scientists, and revealed its own plans to develop drugs for neglected diseases using AI, entering a competitive field of AI-driven drug discovery.
Anthropic launched Claude Science, a flagship product for scientific research that can autonomously carry out tasks in computational biology and drug development, signaling a major bet on AI for science.
LifeBioSciences has dosed the first patient in a Phase 1 trial of ER-100, an epigenetic restoration drug candidate for optic neuropathies, marking a milestone in the development of therapies for vision impairment.
David Sinclair plans to test an oral epigenetic reprogramming drug, SL-100, in the XPrize competition for whole-body rejuvenation, aiming for a 10-year age reversal.
AI is transforming U.S. pharmaceutical R&D by accelerating drug discovery, preclinical testing, clinical trials, and regulatory review, with early evidence suggesting it could cut development times by roughly half and reduce costs.
UCLA researchers developed DDL-920, a drug mimicking stroke rehabilitation effects in mice, published in Nature Communications. This breakthrough targets parvalbumin neurons to restore gamma oscillations and improve movement control.